Possible Prognostic Benefit from ABMT in First Remission Adult Acute Lymphoblastic Leukemia

2000 ◽  
pp. 217-225
Author(s):  
R. Bassan ◽  
A. Rambaldi ◽  
T. Lerede ◽  
E. Di Bona ◽  
G. Rossi ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Adult Acute Lymphoblastic Leukemia ◽  
First Remission

The presence of TEL/AML1 rearrangement and cryptic deletion of the TEL gene in adult acute lymphoblastic leukemia (ALL)

2005 ◽  
Vol 162 (2) ◽  
pp. 176-178 ◽  
Author(s):  
Dong Soon Lee ◽  
Young Ree Kim ◽  
Hyung Kyun Cho ◽  
Chung Kee Lee ◽  
Jee Hyung Lee ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Adult Acute Lymphoblastic Leukemia

scholarly journals Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report

Blood ◽  
1991 ◽  
Vol 78 (11) ◽  
pp. 2814-2822 ◽  
Author(s):  
CA Linker ◽  
LJ Levitt ◽  
M O'Donnell ◽  
SJ Forman ◽  
CA Ries
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Disease Free Survival ◽  
Remission Induction ◽  
Cell Phenotype ◽  
Free Survival ◽  
Prognostic Features ◽  
Adult Acute Lymphoblastic Leukemia ◽  
Disease Free

Abstract We treated 109 patients with adult acute lymphoblastic leukemia (ALL) diagnosed by histochemical and immunologic techniques. Patients were excluded only for age greater than 50 years and Burkitt's leukemia. Treatment included a four-drug remission induction phase followed by alternating cycles of noncrossresistant chemotherapy and prolonged oral maintenance therapy. Eighty-eight percent of patients entered complete remission. With a median follow-up of 77 months (range, 48 to 111 months), 42% +/- 6% (SEM) of patients achieving remission are projected to remain disease-free at 5 years, and disease-free survival for all patients entered on study is 35% +/- 5%. Failure to achieve remission within the first 4 weeks of therapy and the presence of the Philadelphia chromosome are associated with a 100% risk of relapse. Remission patients with neither of these adverse features have a 48% +/- 6% probability of remaining in continuous remission for 5 years. Patients with T-cell phenotype have a favorable prognosis with 59% +/- 13% of patients achieving remission remaining disease-free compared with 31% +/- 7% of CALLA-positive patients. Intensive chemotherapy may produce prolonged disease-free survival in a sizable fraction of adults with ALL. Improved therapy is needed, especially for patients with adverse prognostic features.

scholarly journals Influence of detection of pretreatment cytogenetic abnormalities on first complete remission and survival in adult acute lymphoblastic leukemia

2011 ◽  
Vol 28 (3) ◽  
pp. 176-185
Author(s):  
Milena Georgieva Velizarova ◽  
Evgueniy A. Hadjiev ◽  
Kamelia V. Alexandrova ◽  
Ivanka I. Dimova ◽  
Draga I. Toncheva ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Complete Remission ◽  
Lymphoblastic Leukemia ◽  
Cytogenetic Abnormalities ◽  
Adult Acute Lymphoblastic Leukemia ◽  
First Complete Remission

scholarly journals Adult acute lymphoblastic leukemia

2009 ◽  
Vol 31 ◽  
Author(s):  
Robin Foà ◽  
Sabina Chiaretti ◽  
Anna Guarini ◽  
Antonella Vitale
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Adult Acute Lymphoblastic Leukemia
Sign in / Sign up

Export Citation Format

Share Document